Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Post by Brinkleyon Jul 24, 2005 11:25am
147 Views
Post# 9315093

Interesting Insider positions

Interesting Insider positionsI get a report from TD called INK research (Insider news and knowledge.) It shows when there has been Director,CEO,CFO and major shareholder buying and selling. I was surprised to see no selling at all from anyone over the last year.(as far back as my report shows.) In fact Peter(CEO) purchase shares on the market in November, December and March. He has a lot of options and is still buying. Hbm Bioventures own 22.6 million shares and haven't sold 1 in the last year I was surprised because I thought they were the ones selling on the spikes. Vengrowth has 20 million shares and 10 million warrents and again they have not sold 1 share in the last year. CEO,CFO,Directors, Hbm bioventures(huge biotech investor)Vengrowth(major Canadian Biotech investor) Have all taken large positions in this company. I believe they are all very intellegent people and know more about Adherex its patents and potential to develop drugs than anyone else. I don't even think that is debatable. NONE! of them have sold a single share in the last year in fact the CEO,Directors and CFO have added shares on the open market. I find that very revealing
Bullboard Posts